The Adis journal Drugs in R&D has been transformed from fee-based access to open access (OA), according to its parent company Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to professionals in the pharmaceutical and biotech fields. The conversion makes Drugs in R&D the company's first publication to embrace OA. All of the journal's content published today forward will be available online free of charge.
"We reinvented Drugs in R&D as an open access journal to give researchers unrestricted access to all of its peer-reviewed content," said Anton van Rensburg, MSc, Editor, Drugs in R&D. "With increased pressure today for more speed and transparency in drug research and development, Drugs in R&D is an ideal outlet to further the cause by making its content publically accessible and free for all."
For more than 40 years, medical and scientific researchers have turned to Adis journals for their high quality, peer-reviewed content. First launched in 1999 on a subscription and pay-per-view basis, Drugs in R&D includes original research and reviews from all phases of clinical development. The journal is Medline indexed and available on both Ovid and AdisOnline providing high global visibility.
"Unlike many new-to-market OA publications Drugs in R&D is already a well regarded and trusted source of clinical information by scientific and medical researchers," said Iain Spray, Product Manager, Adis. "This makes it a high-value platform for researchers looking to make their findings available to the global research community."
The Adis team has extensive experience with rapid publication and applies this expertise to Drugs in R&D by offering an optional Rapid Publishing Service which allows publication of new research in as little as four weeks from submission. Before any submitted article is published, it must be accepted by a panel of independent peer reviewers. The company then charges a nominal fee to cover the cost of publication.
"Our conversion is but a tiny part of a much larger movement aimed at making more research available faster and to more people," added Spray.
Small brain-penetrating molecule offers hope for treating aggressive brain tumors